LYB002
/ Luye Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 03, 2023
The Safety and Immunogenicity Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB002
(clinicaltrials.gov)
- P1 | N=210 | Active, not recruiting | Sponsor: Guangzhou Patronus Biotech Co., Ltd.
New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1